CA2694600A1 - Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps - Google Patents
Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps Download PDFInfo
- Publication number
- CA2694600A1 CA2694600A1 CA2694600A CA2694600A CA2694600A1 CA 2694600 A1 CA2694600 A1 CA 2694600A1 CA 2694600 A CA2694600 A CA 2694600A CA 2694600 A CA2694600 A CA 2694600A CA 2694600 A1 CA2694600 A1 CA 2694600A1
- Authority
- CA
- Canada
- Prior art keywords
- bmp
- polymer
- group
- complex
- complex according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 91
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 50
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 49
- 230000002188 osteogenic effect Effects 0.000 title description 6
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims abstract description 31
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims abstract description 31
- 229940112869 bone morphogenetic protein Drugs 0.000 claims abstract description 31
- 150000004676 glycans Polymers 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 18
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 15
- 239000012736 aqueous medium Substances 0.000 claims abstract description 4
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 81
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 81
- 150000001720 carbohydrates Chemical group 0.000 claims description 25
- 229920001282 polysaccharide Polymers 0.000 claims description 20
- 239000005017 polysaccharide Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 229920002307 Dextran Polymers 0.000 claims description 13
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims description 12
- 150000007942 carboxylates Chemical class 0.000 claims description 12
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 10
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 claims description 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- -1 phosphates phosphonates Chemical class 0.000 claims description 9
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 8
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 230000004071 biological effect Effects 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
- 150000007513 acids Chemical class 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 235000010980 cellulose Nutrition 0.000 claims description 6
- 229920002674 hyaluronan Polymers 0.000 claims description 6
- 125000001165 hydrophobic group Chemical group 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 5
- 108010090254 Growth Differentiation Factor 5 Proteins 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
- 235000021317 phosphate Nutrition 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 101710204282 Growth/differentiation factor 5 Proteins 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 230000011164 ossification Effects 0.000 claims description 4
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims description 4
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 3
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229940024606 amino acid Drugs 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 150000007970 thio esters Chemical class 0.000 claims description 2
- 150000003568 thioethers Chemical class 0.000 claims description 2
- 239000002904 solvent Substances 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000004804 polysaccharides Polymers 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 52
- 235000018102 proteins Nutrition 0.000 description 46
- 238000006467 substitution reaction Methods 0.000 description 19
- 239000000872 buffer Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- 239000000178 monomer Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 230000005012 migration Effects 0.000 description 8
- 238000013508 migration Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 108090001109 Thermolysin Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000006641 stabilisation Effects 0.000 description 7
- 238000011105 stabilization Methods 0.000 description 7
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-DYCDLGHISA-M Sodium hydroxide-d Chemical compound [Na+].[2H][O-] HEMHJVSKTPXQMS-DYCDLGHISA-M 0.000 description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 6
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000003098 myoblast Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical group CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical class C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UDQCRUSSQAXPJY-VIFPVBQESA-N (2s)-2-amino-3-(1h-indol-3-yl)propan-1-ol Chemical compound C1=CC=C2C(C[C@@H](CO)N)=CNC2=C1 UDQCRUSSQAXPJY-VIFPVBQESA-N 0.000 description 1
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 1
- WRAUXDQDRDJTKM-UHFFFAOYSA-N 2-(1h-indol-2-yl)ethanamine Chemical compound C1=CC=C2NC(CCN)=CC2=C1 WRAUXDQDRDJTKM-UHFFFAOYSA-N 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000722985 Fidia Species 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 238000005618 Fries rearrangement reaction Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 206010053317 Hydrophobia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- JLSKPBDKNIXMBS-VIFPVBQESA-N L-tryptophanamide Chemical compound C1=CC=C2C(C[C@H](N)C(N)=O)=CNC2=C1 JLSKPBDKNIXMBS-VIFPVBQESA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100437777 Mus musculus Bmpr1a gene Proteins 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 208000002565 Open Fractures Diseases 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 102000007374 Smad Proteins Human genes 0.000 description 1
- 108010007945 Smad Proteins Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241001447056 Uristes Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 229920005603 alternating copolymer Polymers 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003171 anti-complementary effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229960001843 dibotermin alfa Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000045896 human BMP2 Human genes 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000010494 opalescence Effects 0.000 description 1
- 230000004819 osteoinduction Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229920006301 statistical copolymer Polymers 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B11/00—Preparation of cellulose ethers
- C08B11/02—Alkyl or cycloalkyl ethers
- C08B11/04—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals
- C08B11/10—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals
- C08B11/12—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals substituted with carboxylic radicals, e.g. carboxymethylcellulose [CMC]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95240707P | 2007-07-27 | 2007-07-27 | |
| FR0705536A FR2919188B1 (fr) | 2007-07-27 | 2007-07-27 | Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps |
| US60/952,407 | 2007-07-27 | ||
| FR07/05536 | 2007-07-27 | ||
| PCT/EP2008/059832 WO2009016131A1 (fr) | 2007-07-27 | 2008-07-25 | COMPLEXES ENTRE UN POLYMÈRE AMPHIPHILE ET UNE PROTÉINE OSTÉOGÉNIQUE APPARTENANT À LA FAMILLE DES BMPs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2694600A1 true CA2694600A1 (fr) | 2009-02-05 |
Family
ID=38990010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2694600A Abandoned CA2694600A1 (fr) | 2007-07-27 | 2008-07-25 | Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8389661B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2178565A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010534708A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20100051695A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101835493A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008281848A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0813025A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2694600A1 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2919188B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010001104A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2010107203A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009016131A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201001163B (cg-RX-API-DMAC7.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2914305B1 (fr) * | 2007-03-29 | 2009-07-03 | Proteins & Peptides Man | Dextran fonctionnalise par des amino-acides hydrophobes. |
| US20120041079A1 (en) * | 2006-09-26 | 2012-02-16 | Adocia | Dextran functionalized by hydrophobic amino acids |
| AU2007234612B2 (en) * | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
| CA2695697A1 (en) | 2007-08-07 | 2009-02-12 | Advanced Technologies And Regenerative Medicine, Llc | Protein formulations comprising gdf-5 in aqueous acidic solution |
| BRPI0911048A2 (pt) * | 2008-04-14 | 2015-12-29 | Atrm Llc | formulações líquidas tamponadas de gdf-5 |
| EP2288370A1 (fr) * | 2008-04-14 | 2011-03-02 | Adocia | Composition osteogenique comprenant un complexe facteur de croissance/polymere amphiphile un sel soluble de cation e un support organique |
| EP2288371A1 (fr) * | 2008-04-14 | 2011-03-02 | Adocia | Composition osteogenique comprenant un facteur de croissance un sel soluble de cation et un support organique |
| FR2934999B1 (fr) * | 2008-08-13 | 2011-07-29 | Adocia | Polysaccharides fonctionnalises par des derives du tryptophane |
| EP2349338A2 (fr) * | 2008-09-26 | 2011-08-03 | Adocia | Complexe constitue d'un polysaccharide et d'une hpb |
| FR2948573B1 (fr) * | 2009-07-31 | 2011-11-18 | Adocia | Nouvelle forme d'administration de complexes de proteines osteogeniques |
| US8529933B2 (en) | 2009-07-27 | 2013-09-10 | Warsaw Orthopedic, Inc. | Biphasic calcium phosphate cement for drug delivery |
| JP2011030455A (ja) * | 2009-07-30 | 2011-02-17 | Uha Mikakuto Co Ltd | トリプトファン−ヒアルロン酸食品素材及びトリプトファン高含有ペプチド−ヒアルロン酸食品素材並びにそれらの製造方法 |
| FR2952375A1 (fr) * | 2009-11-10 | 2011-05-13 | Adocia | Polysaccharides comportant des groupes fonctionnels carboxyles substitues par esterification par un derive d'alcool hydrophobe |
| FR2956116A1 (fr) * | 2010-02-09 | 2011-08-12 | Adocia | Complexes polysaccharide/bmp-7 solubles a ph physiologique |
| US20130143821A1 (en) * | 2010-02-04 | 2013-06-06 | University Of Tennessee Research Foundation | Hydrophobically-modified hyaluronan and methods of making and using thereof |
| FR2958647B1 (fr) | 2010-04-08 | 2013-08-23 | Adocia | Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive hydrophobe porte par un spacer au moins trivalent. |
| BR112012019580A2 (pt) * | 2010-02-09 | 2020-08-18 | Adocia | "polissacarídeos antônicos funcionalizados por pelo menos dois grupos hidrofóbicos carreados por pelo menos um espaçador trivalente |
| AU2011284657B2 (en) * | 2010-07-30 | 2013-11-14 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Drug delivery devices and growth factor formulations for accelerated wound healing |
| CN101942101A (zh) * | 2010-09-02 | 2011-01-12 | 四川大学 | 含疏水烷基侧链的两亲性聚电解质接枝物制备方法 |
| JP2012082180A (ja) * | 2010-10-14 | 2012-04-26 | Nagoya Univ | 骨再生用自己組織化ペプチドハイドロゲル |
| BR112014002986A2 (pt) * | 2011-08-10 | 2017-06-13 | Adocia | composição sob a forma de uma solução injetável, e formulação de dose única |
| CN107583039A (zh) | 2012-01-09 | 2018-01-16 | 阿道恰公司 | Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液 |
| US9815912B2 (en) * | 2012-03-19 | 2017-11-14 | University Of Massachusetts | Hydrophilic modification of water insoluble polysaccharide as surface-active agents |
| US20150314003A2 (en) | 2012-08-09 | 2015-11-05 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer |
| SG10201703742SA (en) * | 2012-11-13 | 2017-06-29 | Adocia | Substituted anionic compounds consisting of a backbone consisting of a discrete number of saccharide units |
| US9700599B2 (en) | 2012-11-13 | 2017-07-11 | Adocia | Rapid-acting insulin formulation comprising a substituted anionic compound |
| FR3020947B1 (fr) | 2014-05-14 | 2018-08-31 | Adocia | Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations |
| US9795678B2 (en) | 2014-05-14 | 2017-10-24 | Adocia | Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound |
| FR3043557B1 (fr) | 2015-11-16 | 2019-05-31 | Adocia | Composition a action rapide d'insuline comprenant un citrate substitue |
| CN105820270A (zh) * | 2016-03-30 | 2016-08-03 | 中国药科大学 | 硫酸化透明质酰脂肪烃胺 |
| CN119112883B (zh) * | 2024-09-12 | 2025-06-06 | 华南农业大学 | L-色氨酰胺盐酸盐的应用和抗菌组合物 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2808405A (en) | 1955-03-11 | 1957-10-01 | Ohio Commw Eng Co | Acylated amino acid esters of dextran products and method of making same |
| DE4136324A1 (de) | 1991-11-05 | 1993-05-13 | Hoechst Ag | Dextranderivate als adsorptionsmittel fuer gallensaeuren, mit gallensaeuren beladene dextranderivate und verfahren zu deren herstellung sowie deren anwendung als arzneimittel |
| US6573251B2 (en) | 1994-03-30 | 2003-06-03 | Denis Barritault | Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate |
| DE4433101A1 (de) | 1994-09-16 | 1996-03-21 | Bauer Kurt Heinz Prof Dr | Wasserlösliche Dextranfettsäureester und ihre Verwendung als Solubilisatoren |
| CA2192725C (en) | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
| US20040132653A1 (en) | 1997-01-30 | 2004-07-08 | Biopharm Gmbh | Lyophilized composition of bone morphogenetic factor human MP52 |
| AU7466998A (en) | 1997-04-14 | 1998-11-11 | Byron E. Anderson | Method and material for inhibiting complement |
| BR9815239B1 (pt) * | 1997-10-03 | 2010-07-13 | composição de liberação de droga polimérica biodegradável aquosa compreendendo um polìmero tribloco biodegradável do tipo aba- ou bab. | |
| FR2772382B1 (fr) | 1997-12-11 | 2000-03-03 | Solutions | Derives de dextrane, leur procede de preparation et leurs applications comme medicaments a action biologique specifique |
| US6423345B2 (en) * | 1998-04-30 | 2002-07-23 | Acusphere, Inc. | Matrices formed of polymer and hydrophobic compounds for use in drug delivery |
| FR2781485B1 (fr) * | 1998-07-21 | 2003-08-08 | Denis Barritault | Polymeres biocompatibles leur procede de preparation et les compositions les contenant |
| JP4548623B2 (ja) | 1999-02-24 | 2010-09-22 | 多木化学株式会社 | 生体材料 |
| KR100844295B1 (ko) | 1999-06-04 | 2008-07-07 | 알자 코포레이션 | 이식성 겔 조성물 및 이의 제조방법 |
| FR2794649B1 (fr) * | 1999-06-11 | 2003-04-11 | Solutions | Biomateriau a base d'un derive de dextrane insolubilise et d'un facteur de croissance, son procede de preparation et ses applications |
| ATE271886T1 (de) * | 1999-10-15 | 2004-08-15 | Inst Genetics Llc | Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine |
| EP1481695A1 (en) * | 1999-10-15 | 2004-12-01 | Genetics Institute, LLC | Formulations of hyaluronic acid for delivery of osteogenic proteins |
| AU2002245205B2 (en) * | 2000-10-19 | 2007-07-19 | Ecole Polytechnique Federale De Lausanne | Block copolymers for multifunctional self-assembled systems |
| WO2003011226A2 (en) * | 2001-08-01 | 2003-02-13 | Smithkline Beecham Corporation | Products and drug delivery vehicles |
| MXPA04011337A (es) * | 2002-05-17 | 2005-07-01 | Wyeth Corp | Portadores de acido hialuronico solidos y susceptibles de ser inyectados para la liberacion de proteinas osteogenicas. |
| WO2005056039A1 (en) | 2003-12-05 | 2005-06-23 | Northwestern University | Self-assembling peptide amphiphiles and related methods for growth factor delivery |
| FR2914305B1 (fr) | 2007-03-29 | 2009-07-03 | Proteins & Peptides Man | Dextran fonctionnalise par des amino-acides hydrophobes. |
| FR2891149B1 (fr) * | 2005-09-26 | 2007-11-30 | Biodex Sarl | Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes. |
| EP2007816A1 (fr) * | 2006-04-07 | 2008-12-31 | Adocia | Polysaccharides bifonctionnalises |
| US20080102128A1 (en) * | 2006-07-28 | 2008-05-01 | Flamel Technologies, Inc. | Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them |
-
2007
- 2007-07-27 FR FR0705536A patent/FR2919188B1/fr not_active Expired - Fee Related
-
2008
- 2008-07-25 MX MX2010001104A patent/MX2010001104A/es active IP Right Grant
- 2008-07-25 BR BRPI0813025A patent/BRPI0813025A2/pt not_active IP Right Cessation
- 2008-07-25 RU RU2010107203/15A patent/RU2010107203A/ru not_active Application Discontinuation
- 2008-07-25 AU AU2008281848A patent/AU2008281848A1/en not_active Abandoned
- 2008-07-25 WO PCT/EP2008/059832 patent/WO2009016131A1/fr not_active Ceased
- 2008-07-25 JP JP2010518637A patent/JP2010534708A/ja active Pending
- 2008-07-25 CN CN200880107383A patent/CN101835493A/zh active Pending
- 2008-07-25 US US12/219,679 patent/US8389661B2/en not_active Expired - Fee Related
- 2008-07-25 CA CA2694600A patent/CA2694600A1/fr not_active Abandoned
- 2008-07-25 KR KR1020107004494A patent/KR20100051695A/ko not_active Withdrawn
- 2008-07-25 EP EP08786481A patent/EP2178565A1/fr not_active Withdrawn
-
2010
- 2010-02-17 ZA ZA201001163A patent/ZA201001163B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009016131A1 (fr) | 2009-02-05 |
| FR2919188A1 (fr) | 2009-01-30 |
| MX2010001104A (es) | 2010-04-01 |
| FR2919188B1 (fr) | 2010-02-26 |
| US20090048412A1 (en) | 2009-02-19 |
| KR20100051695A (ko) | 2010-05-17 |
| EP2178565A1 (fr) | 2010-04-28 |
| BRPI0813025A2 (pt) | 2017-08-08 |
| CN101835493A (zh) | 2010-09-15 |
| AU2008281848A1 (en) | 2009-02-05 |
| ZA201001163B (en) | 2010-10-27 |
| RU2010107203A (ru) | 2011-09-10 |
| JP2010534708A (ja) | 2010-11-11 |
| US8389661B2 (en) | 2013-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2694600A1 (fr) | Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps | |
| CA2720203A1 (fr) | Composition osteogenique comprenant un complexe facteur de croissance/polymere amphiphile un sel soluble de cation et un support organique | |
| US8691793B2 (en) | Modified macromolecules and associated methods of synthesis and use | |
| US6610669B1 (en) | Water insoluble derivatives of polyanionic polysaccharides | |
| CA2744150A1 (fr) | Nouvelle forme d'administration de complexes de proteines osteogeniques | |
| KR101121675B1 (ko) | 신규 생체적합물질, 그의 제조방법 및 용도 | |
| US20100226985A1 (en) | Viscoelastic aqueous gels comprising microspheres | |
| KR20150111372A (ko) | 주사 시술용 보형물 | |
| WO2007034320A2 (fr) | Complexe polymere amphiphile-pdgf | |
| FR2873379A1 (fr) | Procede de preparation d'acide hyaluronique reticule, acide hyaluronique reticule susceptible d'etre obtenu par ledit procede, implant contenant ledit acide hyaluronique reticule, et son utilisation | |
| CA2738274A1 (fr) | Complexe constitue d'un polysaccharide et d'une hpb | |
| FR3035327A1 (fr) | Solution aqueuse homogene de chitosane ou derive de chitosane injectable presentant un ph proche du ph physiologique | |
| Jain et al. | Thiolated chitosan as an improved bioadhesive polymer in drug delivery | |
| JP2024540178A (ja) | 修飾アルギン酸塩、ならびにその製造方法および使用方法 | |
| EP2501389A1 (fr) | Complexes polysaccharide / bmp solubles a ph physiologique | |
| JP2017528296A (ja) | グリコサミノグリカンおよびタンパク質を含む組成物 | |
| FR2933306A1 (fr) | Composition osteogenique comprenant un complexe facteur de croissance polysaccharide anionique, un sel soluble de cation et une matrice organique | |
| FR2937863A1 (fr) | Composition osteogenique comprenant un complexe facteur de croissance polysaccharide anionique, un sel soluble de cation et un gel | |
| FR2944447A1 (fr) | Composition osteogenique comprenant un facteur de croissance un sel soluble de cation et un gel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20130725 |